| (Values in U.S. Thousands) | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 | Sep, 2015 |
| Sales | -9,999,000 | 1,060 | 110 | 0 | 0 |
| Sales Growth | -943,401.89% | +863.64% | unch | unch | unch |
| Net Income | -9,999,000 | -13,340 | -12,220 | -8,480 | -22,210 |
| Net Income Growth | -74,855.02% | -9.17% | -44.10% | +61.82% | -102.09% |
Tobira Therapeutics
(TBRA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Tobira Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to treat liver disease, inflammation, liver fibrosis and human immunodeficiency virus. Tobira Therapeutics, Inc., formerly known as Regado Biosciences, Inc., is headquartered in San Francisco, CA.
Fiscal Year End Date: 12/31